Intellia Therapeutics, Inc. (NTLA) Q3 2025 10-Q Quarterly Report
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
In Vitro & In Vivo Diagnostic SubstancesSEC EDGAR Intellia Therapeutics, Inc. (NTLA) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Intellia Therapeutics, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New clinical hold risk: FDA placed hold on MAGNITUDE and MAGNITUDE-2 Phase 3 trials for ATTR amyloidosis after Grade 4 liver events and patient death
- • Most updated risk: Delays in clinical development due to evolving FDA requirements and additional preclinical data demands for CRISPR therapies
- • Regulatory risk: FDA issued final 2024 guidance on Human Gene Therapy Products incorporating genome editing, affecting regulatory pathways and follow-up requirements
- • Operational risk: Challenges enrolling patients in clinical trials and potential suspension due to safety concerns or regulatory noncompliance threaten near-term progress
- • Financial risk: Continued net losses and no revenue from product sales, dependent on resolving clinical hold and successful commercialization to achieve profitability
Get deeper insights on Intellia Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.